Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context

  1. Toth, P.P.
  2. Danese, M.
  3. Villa, G.
  4. Qian, Y.
  5. Beaubrun, A.
  6. Lira, A.
  7. Jansen, J.P.
Aldizkaria:
Journal of Medical Economics

ISSN: 1941-837X,  1369-6998

Argitalpen urtea: 2017

Alea: 20

Zenbakia: 6

Orrialdeak: 555-564

Mota: Artikulua

DOI: 10.1080/13696998.2017.1284078 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus